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Abstract
Introduction: Hospital-based antimicrobial stewardship efforts have traditionally focused on inpatient settings. Antibiotic
prescribing at discharge is often an overlooked area of focus
for antimicrobial stewardship programs. Discharge prescribing optimization is necessary to combat antibiotic overuse.
Methods: This was an observational, retrospective cohort
study at a four–adult community hospital system. Four hundred adult patients admitted with community-acquired pneumonia and discharged with antibiotics were included. The primary outcome was overall (inpatient and discharge) antibiotic
length of therapy. The secondary outcome was percentage
of patients discharged on a fluoroquinolone who had not re-

Introduction
Antimicrobial stewardship programs (ASPs) seek to
optimize antimicrobial use to reduce the risk for
Clostridioides difficile infection, drug toxicities, and the
emergence of drug-resistant pathogens.[1, 2] ASP interventions have historically focused on antibiotic use
during hospitalization. A common target for hospitalbased ASPs is community-acquired pneumonia (CAP)
since it accounts for an estimated 1.6 million hospitalizations annually in the United States and is one of the
top ten causes of mortality.[3, 4] Additionally, the Centers for Disease Control and Prevention (CDC)’s Core
Elements of Hospital Antimicrobial Stewardship Programs specifically designate duration of therapy at discharge in CAP patients as an important target.[5] Contrary to guideline recommendations, many patients
hospitalized with CAP receive greater than five days of
antibiotics with the outpatient duration often exceeding the inpatient length of therapy.[6-11]

ceived one in the hospital. Descriptive statistics were utilized.
Results: The median total antibiotic length of therapy was
9.5 days (IQR 8, 11). The median inpatient and discharge antibiotic lengths of therapy were 4 days (IQR 3, 5) and 5 days
(IQR 5, 7), respectively. Of the 108 patients prescribed a fluoroquinolone at discharge, 43% (46/108) had not previously
received a fluoroquinolone while hospitalized.
Conclusion: Both length of therapy and fluoroquinolone
stewardship at discharge may represent possible antimicrobial stewardship targets in community-acquired pneumonia
patients.

been previously described; this is particularly concerning given the myriad of toxicities associated with fluoroquinolones and the U.S. Food & Drug Administration (FDA)’s caution against their use.[6, 8, 12] This
has prompted a focus on antimicrobial stewardship efforts at transitions of care to decrease suboptimal antibiotic choice and duration at hospital discharge.[13]
Discharge prescription data can be challenging to capture, limiting the amount of data reported regarding
the total duration of therapy for hospitalized patients
with CAP.[6-8] Therefore, in order to determine current discharge prescribing practices in a health system,
manual review may be necessary. The purpose of this
study was to quantify antimicrobial stewardship opportunities at hospital discharge in patients admitted
for CAP.

Additionally, increases in discharge fluoroquinolone
prescribing rates relative to inpatient settings have
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Methods

Definitions

Study setting and population

Inpatient antibiotic length of therapy was defined
as the number of calendar days for which CAP
antibiotics were administered. CAP antibiotics included penicillin, amoxicillin, amoxicillin/clavulanate,
ampicillin/sulbactam, piperacillin/tazobactam, cefazolin, cephalexin, cefuroxime, ceftriaxone, ceftazidime,
cefdinir, cefpodoxime, azithromycin, doxycycline,
ciprofloxacin, levofloxacin, moxifloxacin, linezolid,
and vancomycin. Discharge antibiotic length of therapy was determined based on the prescribed duration from the discharge prescription. If more than one
antibiotic was prescribed at discharge, length of therapy for both agents was considered, and the longer
duration based on calendar days of either agent was
utilized. For example, if a patient was prescribed
one day of azithromycin and five days of amoxicillin/clavulanate, the discharge length of therapy was
considered to be five days. Hospital length of stay was
collected based on calendar days for which the patient
was hospitalized.

This was a retrospective, observational study conducted at Norton Healthcare, a not-for-profit community healthcare system, in Louisville, Kentucky. The
system includes four adult hospitals with approximately 1,600 licensed beds. All hospitals are within the
Louisville metropolitan area and are served by a central ASP comprising four full-time infectious diseases
pharmacists, one infectious diseases physician, and one
infectious diseases pharmacy resident. Antimicrobial
stewardship staff perform prospective audit and feedback. Specifically regarding pneumonia, the ASP has a
local guideline in place, which recommends 5 days as
an appropriate length of therapy in CAP patients who
are clinically stable and have been afebrile >48 hours.
Though not explicitly recommended in the guideline,
procalcitonin is mentioned as a possible guide in determining length of therapy, and discontinuation of antibiotics is encouraged if procalcitonin is ≤0.5 ng/mL
or has decreased ≥80% from a baseline >10 ng/mL.
The ASP currently has no defined process for addressing discharge antibiotic prescribing.
Patients ≥18 years of age were included if they were
admitted with a diagnosis-related group code for CAP
(177, 178, 179, 193, 194, or 195) between June 2018 and
June 2019 and were discharged on an antibiotic for
CAP. Patients were excluded if they had any of the following complicating factors: cystic fibrosis, lung transplant, empyema, lung abscess, receiving chemotherapy, HIV, a respiratory culture with Pseudomonas spp.,
pregnancy, incarceration, inpatient mortality, or if they
were discharged on parenteral antibiotic therapy or
systemic antifungals other than fluconazole. Patients
could be included more than once in the study period.
Patients meeting inclusion and exclusion criteria were
randomized, and samples of 100 patients from each of
the four hospitals were included in the final cohort.
The study was exempted from informed consent by
the University of Louisville Institutional Review Board
(IRB 19.1072).
Study outcomes
The primary outcome was the total antibiotic length
of therapy for CAP. The secondary outcome was the
percentage of patients discharged on a fluoroquinolone
when a fluoroquinolone was not administered during the hospitalization. Post-hoc exploratory analysis
included the distribution of discharge antibiotic days
of therapy. Data were characterized with descriptive
statistics.
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In addition to antibiotic therapy information, age, sex,
first procalcitonin, admission to the intensive care unit
(ICU), and blood culture information were collected if
available.

Results
To reach the target sample size, 445 hospital admissions were screened. Forty-five patients were excluded, with the most common reason being the receipt of chemotherapy (n=31), followed by lung abscess
(n=4), Pseudomonas spp. infection (n=3), HIV (n=3),
empyema (n=2), lung transplant (n=1), and being discharged on parenteral antibiotics (n=1). The median
age was 68 years (interquartile range [IQR] 56, 79), and
53% of the cohort was female. The median hospital
length of stay was 3 days (IQR 2, 4).
The median total antibiotic length of therapy was 9.5
days (IQR 8, 11). The distribution of the total antibiotic length of therapy is represented in Figure 1. Most
patients (97%) received more than 5 days of antibiotic
therapy. The median inpatient and discharge antibiotic
lengths of therapy were 4 days (IQR 3, 5) and 5 days
(IQR 5, 7), respectively. At hospital discharge, 76% of
patients received either 5 days, 7 days, or 10 days of
additional antibiotic therapy (Figure 2).
At least one dose of a fluoroquinolone was administered in 22% (n=86) of all patients during hospital admission. Thirty-one percent (27/86) of those patients
received only a single dose of a fluoroquinolone prior
to switching to an alternative antibiotic. Of 108 patients
(27%) who were prescribed a fluoroquinolone at discharge, 43% (46/108) had not previously received a flu-
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Figure 1. Distribution of total antibiotic length of therapy for
community-acquired bacterial pneumonia.

Figure 2. Distribution of discharge antibiotic length of therapy for
community-acquired bacterial pneumonia

oroquinolone while inpatient, translating to a new start
rate of 11.5% (46/400) among the entire cohort. Antimicrobials utilized at hospital discharge can be found
in Table 1.

Discussion

Procalcitonin was collected in 217 patients, with 24.4%
of initial values resulting ≥0.5 ng/mL. Procalcitonin
was ordered at a median of hospital day 2. A small
number (n=10, 2.5%) of patients were admitted to the
ICU. Blood cultures were collected in 86.5% of patients.
Growth from blood cultures with was observed in 2 patients. In both cases Streptococcus pneumoniae was isolated.

Table 1. Choice of discharge antimicrobial.

Discharge antibiotic∗
Total
Penicillin
Amoxicillin
Amoxicillin/clavulanate
Cephalexin
Cefuroxime
Cefdinir
Cefpodoxime
Azithromycin
Doxycycline
Ciprofloxacin
Levofloxacin
Moxifloxacin
Linezolid

n (%)
400
0 (0.0)
8 (2.0)
140 (35.0)
7 (1.8)
4 (1.0)
72 (18.0)
0 (0.0)
65 (16.3)
23 (5.8)
3 (0.8)
105 (26.3)
0 (0.0)
1 (0.3)

∗ If patients received multiple antibiotics
at discharge, this was collected.
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We found that patients hospitalized for CAP who completed their antibiotic course after hospital discharge
received a median 9.5 days of total antibiotic therapy. The 2019 American Thoracic Society and Infectious Diseases Society of America guidelines recommend that antibiotic therapy should be continued until
patients achieve clinical stability and for a minimum 5
days.[11] A total duration of 5 days is likely adequate
for most patients discharged on oral antibiotics as most
achieve clinical stability within 48 to 72 hours.[10] In
this cohort, the median length of stay was 3 days. Using hospital discharge as a surrogate for clinical stability, shorter durations likely could have been appropriate in many patients. Additionally, relatively few patients had documented elevations in procalcitonin or
required ICU admission, possibly indicating that prolonged durations of therapy were likely unnecessary
in the overall cohort.[14] Despite these assumptions,
97% of patients received longer than 5 days of antibiotic therapy.
Excessive duration of therapy for CAP has also been
observed in other studies.[8, 9, 12] Yi et al. found that
more than 67% of patients with CAP received >7 days
of therapy.[8] More recently, Vaughn et al. described a
large cohort, in which 63% of antibiotic overuse days
were after discharge.[9] A large retrospective Veteran’s
Affairs study, which also included assessment for clinical stability at discharge, also found that 86.1% of CAP
patients received treatment that was discordant with
guidelines.[6] Overall, excessive prescribing has been
observed in both regional and national studies.
The majority of antibiotic exposure occurred in the outpatient setting, and the duration of antibiotic therapy at
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discharge appeared to be selected based on fixed durations. This was also observed in a large study in Michigan, where authors found prescribers “resetting the
clock” and ordering 5, 7, or 10 days of therapy in 45%
of patients at discharge.[7] These same fixed outpatient
durations were selected in an even larger percentage
of our cohort (76%). This phenomenon may speak to
prescribing convention driving decision-making rather
than a patient-specific assessment.[15]
A recent report from the Michigan Hospital Medicine
Safety Consortium described targeted efforts to decrease antimicrobial length of therapy in uncomplicated CAP patients, as this had previously been identified as an area of opportunity to improve care within
the state.[16] The group provided data, education, and
pay incentives to participating hospitals and demonstrated an increase in guideline-compliant five-day
treatment courses from 22.1% to 45.9%.[16] Additionally, a decrease in short-term antibiotic-associated adverse effects was observed, demonstrating another potential advantage of shorter durations of antibiotic therapy.[16] Though these results are impressive, the authors point out that their financial support from an insurance company made the program possible, and this
may not be a viable strategy for all institutions.
Fluoroquinolones are key targets for antimicrobial
stewardship programs given their FDA safety warnings, association with C. difficile infection, and propensity for inducing antimicrobial resistance.[12, 17, 18]
Despite associated risks, many patients were transitioned to a fluoroquinolone at hospital discharge. The
rate of new fluoroquinolone starts (11.5%, 46/400) was
comparable to that found by Vaughn et al. for hospitals
with fluoroquinolone stewardship programs (17%), but
less than the increase in fluoroquinolone prescriptions
at discharge reported by Yi et al. (22–24%).[8, 12] The
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lower rates in our cohort were surprising given that
outpatient fluoroquinolone prescribing rates in Kentucky are among the highest in the nation.[19] Still,
even a modest rise in fluoroquinolone prescriptions at
discharge is concerning as non-fluoroquinolone alternatives were utilized in the inpatient setting. Our data
add to the growing body of literature emphasizing the
need for fluoroquinolone stewardship interventions at
hospital discharge. The overall impact of reductions in
inpatient fluoroquinolone use may be offset by new fluoroquinolone starts at hospital discharge.
Our data are consistent with previous reports that antimicrobial stewardship opportunities in discharge prescribing appear to be numerous, in regard to both
length of therapy and choice of antimicrobial. This mirrors the results of previous studies and confirms that
this wide-spread issue of overprescribing exists within
a community health settings. The southern region of
the United States has a higher rate of prescribing than
other areas of the United States, and describing specific areas of antimicrobial stewardship opportunities
may be an aid to providers or antimicrobial stewardship programs.[20] Limitations include the retrospective nature of the study and inclusion based on diagnostic codes, rather than criteria, though this is consistent with methodology used in other studies.[6-10]
Additionally, there was no individual assessment of comorbidities or clinical stability at discharge; thus, it is
unknown whether these factors may have contributed
to prescribing trends.
Future studies should investigate the impact of interventions to optimize discharge prescribing, which
could include clinician education, institutional guidelines, electronic health record support, or prospective
audit-and-feedback.
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